Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term

Perampanel reduces seizure frequency in patients with developmental and epileptic encephalopathy for a long term

Abstract Seizures in patients with developmental and epileptic encephalopathies (DEEs) are often highly resistant to various antiseizure medications. Perampanel (PER) is a novel antiseizure medication that non-competitively inhibits the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor a...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirokazu Yamagishi, Hitoshi Osaka, Kazuhiro Muramatsu, Karin Kojima, Yukifumi Monden, Tadahiro Mitani, Yuta Asakura, Keizo Wakae, Kohei Nagai, Toshihiro Tajima
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Scientific Reports
Subjects:
Perampanel
Lennox-Gastaut syndrome
Epilepsy with myoclonic atonic seizures
Long-term
Efficacy & safety
Online Access:https://doi.org/10.1038/s41598-024-82014-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-82014-5

Similar Items